{
  "functional_evidence_assessment": {
    "variant_id": {
      "Gene": "PARK2",
      "Protein_Change": {
        "ref": "L858R",
        "alt": "H",
        "position": "858"
      },
      "variant_string_id": "PARK2 L858R"
    },
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "Mutations of the gene PARK2, which encodes an E3 ubiquitin ligase, are the most common cause of early-onset Parkinson's disease.Germline mutations in PARK2 lead to familial PD.",
        "judgment": "Yes",
        "reasoning": "The mechanism is clearly defined as mutations causing neurodegenerative diseases like PD."
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "PARK2 mutations decrease the E3 ligase activity, leading to mitotic instability.",
        "judgment": "Yes",
        "reasoning": "The assay reflects the observed pathogenesis."
      },
      {
        "step_name": "Step 3: Evaluate validity of specific instances of assays",
        "extracted_paper_info": "No specific controls were mentioned for this variant's assay in the context of its application to cancer cells.",
        "next_step_or_outcome": "Proceed to Step 4"
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_supporting"
    },
    "overall_conclusion": "The evidence supports a pathogenic role for the PARK2 L858R mutation based on its effect in cancer and familial PD."
  }
}